The table below shows REGENERON PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$14.34B
$14.20B
$13.12B
$12.17B
$16.07B
$8.50B
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$5.85B
$5.13B
$4.44B
$3.59B
$2.86B
$2.65B
SG&A
REGN annual revenue (10-K history)
REGENERON PHARMACEUTICALS, INC. reported annual revenue of $14.34B for fiscal year 2025. That is up 1.0% from $14.20B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $4.86B (FY 2016) to $14.34B. Figures come from the company's audited annual reports as filed with the SEC.
